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Abstract
Background: There is an urgent need of prognosis markers for tuberculosis (TB) to improve treatment strategies.
The results of several studies show that the Interferon (IFN)-g-specific response to the TB antigens of the
QuantiFERON TB Gold (QFT-IT antigens) decreases after successful TB therapy. The objective of this study was to
evaluate whether there are factors other than IFN-g [such as IFN-g inducible protein (IP)-10 which has also been
associated with TB] in response to QFT-IT antigens that can be used as biomarkers for monitoring TB treatment.
Methods: In this exploratory study we assessed the changes in IP-10 secretion in response to QFT-IT antigens and
RD1 peptides selected by computational analysis in 17 patients with active TB at the time of diagnosis and after 6
months of treatment. The IFN-g response to QFT-IT antigens and RD1 selected peptides was evaluated as a control.
A non-parametric Wilcoxon signed-rank test for paired comparisons was used to compare the continuous variables
at the time of diagnosis and at therapy completion. A Chi-square test was used to compare proportions.
Results: We did not observe significant IP-10 changes in whole blood from either NIL or QFT-IT antigen tubes,
after 1-day stimulation, between baseline and therapy completion (p = 0.08 and p = 0.7 respectively). Conversely,
the level of IP-10 release to RD1 selected peptides was significantly different (p = 0.006). Similar results were
obtained when we detected the IFN-g in response to the QFT-IT antigens (p = 0.06) and RD1 selected peptides (p
= 0.0003). The proportion of the IP-10 responders to the QFT-IT antigens did not significantly change between
baseline and therapy completion (p = 0.6), whereas it significantly changed in response to RD1 selected peptides
(p = 0.002). The proportion of IFN-g responders between baseline and therapy completion was not significant for
QFT-IT antigens (p = 0.2), whereas it was significant for the RD1 selected peptides (p = 0.002), confirming previous
observations.
Conclusions: Our preliminary study provides an interesting hypothesis: IP-10 response to RD1 selected peptides
(similar to IFN-g) might be a useful biomarker for monitoring therapy efficacy in patients with active TB. However,
further studies in larger cohorts are needed to confirm the consistency of these study results.
Background
The T cell-based assays using region of difference (RD)1
antigens, such as early secreted antigenic target, 6 kDa
(ESAT-6), and culture filtrate protein, and 10 kDa (CFP-
10), have an evolving niche in detecting Mycobacterium
tuberculosis infection. The RD1 sequence is missing
from M. bovis Bacille Calmette-Guerin (BCG), and this
omission makes these antigens more specific for M.
tuberculosis infection diagnosis than the purified protein
derivative (PPD) [1-3]. The two RD1 antigens, ESAT-6
and CFP-10, have been shown to induce strong Inter-
feron (IFN)-g response during short term incubation in
vitro [3,4]. Based on this principle, there are two com-
mercial kits available for diagnosing tuberculosis (TB)
infection, the QuantiFERON-TB GOLD In-Tube®
(QFT-IT) (Cellestis Ltd., Carnegie, Australia) and T-
SPOT.TB® (Oxford Immunotec, Abingdon, UK). The
performance of these assays is extensively reviewed [5-8]
indicating that they are at least as sensitive as the tuber-
culin skin test (TST) in detecting latent TB infection
(LTBI) and active TB cases.
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Animal and human studies have shown a relationship
between the magnitude of IFN-g responses and myco-
bacterial bacillary load [9,10]. It has, therefore, been pos-
tulated that a decrease in the magnitude of IFN-g
responses to M. tuberculosis specific antigens might be
used as a biomarker of treatment response [11]. How-
ever, studies using serial QuantiFERON-TB Gold tests
or IFN-g ELISPOT assay in adults (performed during
treatment of either LTBI [12-17] or active TB disease
[9,18-26]) in various settings have shown conflicting
results, with IFN-g responses decreasing
[14,15,17-20,22,26], increasing [12,16] or remaining
almost unchanged [13,21,23-25] in response to
treatment.
We developed an in vitro IFN-g immune diagnostic
assay for active TB disease, the novelty of which consists
of the use of multiepitopic RD1 peptides selected by
computational analysis [27-29]. IFN-g response to these
RD1 selected peptides can be detected in individuals
with ongoing M. tuberculosis replication (such as during
active TB disease and/or recent TB infection) and has
been shown to significantly decrease in Human Immu-
nodeficiency Virus (HIV) uninfected [17,18] or infected
individuals [30] during TB prophylaxis and therapy.
It has recently been shown (by others and us) that
IFN-g-inducible protein (IP)-10 is a potential diagnostic
marker [31-37]. An enzyme linked immunosorbant
assay (ELISA), which measures levels of IP-10 in whole
blood after overnight stimulation with TB Antigens of
the QFT-IT format (hereinafter referred to as “QFT-IT
antigens”), has demonstrated to have similar sensitivity
for detecting active TB compared to QFT-IT and to the
IFN-g assay based on RD1 selected peptides in HIV-
uninfected subjects [32]. Higher sensitivity in diagnosing
TB cases for both IP-10-based assays has been described
in HIV-infected subjects compared to the corresponding
IFN-g-based tests [34,36,38]. However, to our knowl-
edge, the kinetics of IP-10 secretion in response to
QFT-IT antigens before and after treatment has never
been investigated.
Azzurri et al [39] have described a decline in the levels
of IP-10 in plasma after successful anti-TB treatment.
Furthermore, the previous observations have demon-
strated that patients with active TB had higher IP-10
levels in the NIL tube (unstimulated whole blood cul-
ture tube used in the QFT-IT assay) compared to
healthy controls [40].
Thus, in this exploratory study involving 17 enrolled
subjects (a subgroup of the 41 HIV-uninfected indivi-
duals previously described [33]), we evaluated whether
or not IP-10 can be a good biomarker for monitoring
TB therapy. Therefore, we assessed the changes of IP-10
levels from the NIL and QFT-IT antigen tubes and RD1
selected peptides stimulated whole blood in patients
with active TB disease at the time of TB diagnosis and
after successful specific treatment. IFN-g response to




This study has been approved by the Institutional Ethi-
cal Committee of the Tuberculosis Research Centre,
Chetput, Chennai TRC-IEC (No: 2006005) and written
consent was obtained from each study subject. Study
subjects were prospectively recruited from the Revised
National Tuberculosis Control Program (RNTCP) cen-
ters from April, 2007 to March, 2008. Subjects who
were diagnosed as pulmonary TB patients at the
RNTCP center were assessed for the study. Individuals
with a previous history of TB, who had undergone TST
in the past 16 months, who had HIV infection, silicosis,
end stage renal disease, leukemia/lymphoma or who
were undergoing immunosuppressive therapy were
excluded from the study.
After registering, the eligible subjects underwent radi-
ological examinations, and three sputum samples were
collected from each. The collected sputum samples were
processed [41], stained for acid fast bacilli (AFB) micro-
scopy by Ziehl-Neelsen method and cultured in Lowen-
stein Jensen (BioMérieux Inc., Marcy I’Etoile, France)
and in liquid MP BacT medium (BioMérieux Inc). The
presence of M. tuberculosis in the positive culture sam-
ples was further confirmed by Gen-probe based PCR
(BioMérieux Inc., Marcy I’Etoile, France) method.
Therefore, active TB was defined as microbiologically
confirmed if the criteria stated above was fulfilled. Con-
versely, patients were classified as having “clinical TB” if
the diagnosis was based on clinical and radiologic cri-
teria (after excluding other diseases) including appropri-
ate response to anti-TB therapy.
Blood was drawn from all the recruited study subjects
for a total blood count, HIV testing and IFN-g- and IP-
10-based assays. All subjects were treated with a stan-
dard regimen of rifampicin, isoniazid, ethambutol and
pyrazinamide for 2 months and then, if the clinical con-
ditions and chest X-rays improved and AFB sputum
conversion occurred, rifampicin and isoniazid were con-
tinued for an additional 4 months [42]. At the end of
six months, sputum samples and blood samples were
collected once again and assessed for their response to
treatment and to the in vitro test, respectively.
Stimulation of whole blood with QFT-IT antigens
A commercial QFT-IT assay (Cellestis) was used to
evaluate the QFT-IT antigen-specific IFN-g and IP-10
secretion. Briefly, one ml of blood was taken into each
of the three tubes: pre-coated either with QFT-IT
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antigens, phytohemaglutinin for the positive control or
no antigen for the negative control (NIL). The blood
samples were drawn between 10 and 11 am and taken
to the laboratory within 2 hours of phlebotomy. The
tubes were incubated for 16-24 hours at 37°C and
plasma were collected after centrifugation and stored at
4°C until tested.
RD1 selected peptides and whole blood cultures
The selection of Human Leukocyte Antigens (HLA)-
class II restricted epitopes of ESAT-6 and CFP-10 M.
tuberculosis proteins was performed by a quantitative,
implemented, HLA peptide-binding motif analysis as
previously described for ESAT-6 [27-29]. Peptides were
synthesized as free amino acid termini using Fmoc
chemistry (ABI, Bergamo, Italy). All synthetic peptides
were purified by reverse-phase chromatography to have
at least 90% purity. Sequence and purity were confirmed
by mass spectrometry and analytical reverse-phase chro-
matography [27]. Lyophilized peptides were diluted in
Dimethyl Sulfoxide (DMSO) at stock concentrations of
10 mg/mL for each peptide and stored at -80°C. RD1
selected peptides were used as follows: a pool of the two
ESAT-6 peptides (at 10 μg/mL each) and a pool of the
three CFP-10 peptides (at 2 μg/mL each). DMSO was
used as a negative control at 10 μg/mL. The whole
blood test was carried out as described [33,36]. Briefly,
aliquots of 0.5 ml per well of heparinised blood in
monoplicate were seeded in a 48-well plate and stimu-
lated with or without RD1 selected peptides, as
described above. Samples were then incubated for 16-24
hours at 37°C in the presence of 5% CO2 when 100 μl
of plasma was harvested.
Indian collaborators were provided with RD1 selected
peptides from the same batch, detailed protocol and
personal training by INMI’s laboratory staff. Inter-site
communication was present throughout the study to
solve any potential problems. Clinicians were blinded to
the laboratory test results and laboratory staff was
blinded to the status of the patients.
IP-10 assay
The IP-10 levels were measured in the plasma samples
using human IP-10 ELISA Set (R&D Sysytems, USA) as
per the manufacturer’s instructions [33,36]. To detect
the chemokines, plasma was diluted 1:10 as a starting
dilution. Further dilutions were performed when neces-
sary. The IP-10 data from QFT-IT antigens or RD1 pep-
tides stimulated culture provided in the text and figures
are reported after subtracting the respective unstimu-
lated controls, which is either the whole blood culture
incubated with the same concentration of DMSO used
to dissolve the peptides for the RD1 selected peptides
stimulated conditions [33,36] or the NIL tube for the
QFT-IT antigens.
Measurement of IFN-g
The QFT-IT ELISA (Cellestis) was performed to mea-
sure the IFN-g levels in the plasma samples following
the manufactures instructions (Cellestis Ltd., Victoria,
Australia). The test results were interpreted using soft-
ware supplied by the manufacturer (Cellestis Ltd., Vic-
toria, Australia). Values above 10 IU/ml were considered
as equal to 10 IU/ml, as indicated by the manufacturers.
The IFN-g data from QFT-IT antigens or RD1 peptides
stimulated culture provided in the text and figures are
reported after subtracting the respective unstimulated
controls, which is either the whole blood culture incu-
bated with the same concentration of DMSO used to
dissolve the peptides for the RD1 peptides stimulated
conditions [33,36] or the NIL tube for the QFT-IT
antigens.
Longitudinal analysis of the IP-10 and IFN-g data
A longitudinal analysis of the IP-10 and IFN-g data was
made considering the highest IP-10 response to either
ESAT-6 or CFP-10 selected peptides per single patient
at both baseline and end of treatment.
Eligibility criteria for the study
Enrolled patients were defined as “eligible” if the experi-
mental data at both, baseline and after 6 months treat-
ment were available. Data analysis was performed only
on the subjects that met the eligibility criteria.
Statistical analysis
The main outcome of the study on IP-10 and IFN-g
production in response to QFT-IT antigens and RD1
selected peptides was expressed as continuous (IU/ml)
or dichotomous (positive/negative) measures. For con-
tinuous measures, the median and interquartile range
(IQR) was calculated. A non-parametric Wilcoxon
signed-rank test was used for paired comparisons. Dif-
ferences were considered significant at p values ≤ 0.05.
For dichotomous measures, chi square was used. For
pair-wise comparisons, differences were considered sig-
nificant at p values ≤ 0.05. SPSS v 14 for Windows
(SPSS Italia Srl, Bologna, Italy) and Prism 4 software
(GraphPad Software 4.0, San Diego, CA, USA) were
used in the analysis.
Results
Characteristics of the subjects included in the study
As previously described [33], a total of 41 HIV-unin-
fected individuals were assessed for this report. How-
ever, only 17 subjects met the eligibility criteria for the
Kabeer et al. BMC Infectious Diseases 2011, 11:135
http://www.biomedcentral.com/1471-2334/11/135
Page 3 of 9
study. The median duration of TB treatment was 6
months (IQR: 6.0-6.1).
The median age of the eligible 17 subjects was 32
years and 9 of them were males (Table 1). Regarding
the microbiological data, 12 (71%) were positive for AFB
sputum microscopy and 16 (94%) were positive to spu-
tum culture. In the remaining 1 subject, diagnosis was
made based on clinical criteria.
All 17 subjects completed the anti-tuberculosis ther-
apy by end of six months. They were negative for AFB
sputum microscopy after 2 months of treatment and at
therapy completion. Radiological examination also con-
firmed their healthy status.
Longitudinal analysis of IP-10 secretion to NIL and DMSO
samples in patients with active TB who were followed
until therapy completion
Azzurri et al [39] have described a decline in the IP-10
levels in plasma after successful anti-TB treatment.
Furthermore, the previous observations have demon-
strated that patients with active TB had higher IP-10
levels in NIL tubes when compared to healthy controls
[40]. Assuming that successful treatment reverts the
IP-10 levels in the unstimulated cultures, we evaluated
the IP-10 level in the plasma from NIL tubes and
DMSO whole blood cultures, after 1-day stimulation,
in the patients at the time of TB diagnosis (T0) and at
therapy completion (T6). As shown in Figure 1, no sig-
nificant changes were observed when comparing the
IP-10 levels in the NIL tubes at T0 (median: 1630;
IQR: 212-2330) to T6 (median: 722; IQR: 326-1581) (p
= 0. 0833) (Figure 1A) or comparing the IP-10 levels
in the DMSO cultures at T0 (median: 1250; IQR: 221-
1898) to T6 (median: 830; IQR: 269-1206) (p = 0.1148)
(Figure 1B). These data indicate the absence of signifi-
cant IP-10 changes in the unstimulated culture in this
longitudinal analysis. Therefore, we evaluated the
changes in QFT-IT and RD1 selected peptides stimu-
lated whole blood.
Longitudinal analysis of IP-10 secretion in response to the
QFT-IT antigens in patients with active TB who were
followed until therapy completion: comparison with IFN-g
results
The level of IP-10 secretion in response to the QFT-IT
antigens did not significantly change from the time of
TB diagnosis (T0) (median: 7137 pg/ml; IQR: 2527-
9756) to the end of treatment (T6) (median: 6969 pg/
ml; IQR: 2299-10148) (p = 0.7) (Figure 2A) Using the
cut-off point of 698 pg/ml, previously found by ROC
analysis in the same Indian setting [35] (Table 2), 16 out
of 17 subjects (94.1%) scored positive for IP-10 at the
time of TB diagnosis (Table 3, Figure 2A). At therapy
completion, the one subject who scored negative to IP-
10 turned positive and three subjects who scored posi-
tive at enrolment became negative (Table 3). Hence, the
number of IP-10 positive subjects at the end of treat-
ment was (14/17, 82.3%) (Table 3).
IFN-g secretion was tested as a control. The level of
IFN-g secretion in response to QFT-IT did not signifi-
cantly change between the baseline (median: 4.38 IU/ml;
IQR: 2.58-10.35) and therapy completion (median: 2.66
IU/ml; IQR: 0.82-4.89) (p = 0.7) (Figure 2B). Using the
commercial cut-off value of 0.35 IU/ml (Table 2), 17
out of 17 subjects (100%) were positive to QFT-IT. At
therapy completion, 3 subjects turned negative. The pro-
portion of positive responders between baseline and
therapy completion (14/17, 82.3%) was not statistically
significant (p = 0.2) (Table 3).
Longitudinal analysis of IP-10 secretion in response to the
RD1 selected peptides in patients with active TB who
were followed until therapy completion: comparison with
the IFN-g results
When considering the highest IP-10 response to either
ESAT-6 or CFP-10 selected peptides per single patient,
the IP-10 secretion was significantly higher at the time
of diagnosis (median: 5116 pg/ml; IQR: 2207-7063) than
at therapy completion(T6) (median: 73 pg/ml; IQR: 0-
5222) (p = 0.0060) (Figure 3A) Using the cut-off point
of 350 pg/ml, previously found by ROC analysis [38]
(Table 2), 16 out of 17 subjects (94.1%) scored positive
for IP-10 at the time of TB diagnosis. At therapy com-
pletion, 9 subjects turned negative, whereas the indivi-
dual who scored negative at enrolment was still negative
after therapy completion. Therefore the proportion of
positive responders significantly differed between
Table 1 Demographic and clinical characteristics of the
subjects enrolled in the study
Parameter Total
N. 17
Age, mean in years (IQR) 32 (25-52)
Sex
Male, Number (%) 9 (52.9)





Culture Results, Number (%)
Positive 16 (94.1)
Negative 1 (5.9)
TB Severity, Number (%)
Mild/Moderate 12 (70.6)
Severe 5 (29.4)
Abbreviations: IQR: interquartile range; TB: tuberculosis; IP: inducible protein;
IFN: interferon; RD: region of difference.
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baseline and therapy completion (7/17, 41.1%) (p =
0.002) (Table 3).
IFN-g secretion was tested as a control. When consid-
ering the highest IFN-g response to either ESAT-6 or
CFP-10 selected peptides for single patient, the IFN-g
secretion was significantly higher at the time of diagno-
sis (median: 2.56 IU/ml; IQR: 1.20-4.18) than at therapy
completion (median: 0.42 IU/ml; IQR: 0.02-1.72) (Figure
3B) (p = 0.0003). With the cut-off value of 0.57 IU/ml,
previously found by ROC analysis [32] (Table 2), 16 out
of 17 subjects (94.1%) scored positive in response to
RD1 selected peptides at the time of TB diagnosis. At
therapy completion, 9 subjects turned negative, whereas
the individual who scored negative at enrolment was
still negative after therapy completion. Therefore, the
proportion of positive responders significantly differed
between baseline and therapy completion (7/17, 41.1%)
(p = 0.002) (Table 3).
When we used the same cut-off value used by the
QFT-IT (0.35 IU/ml), no change was found in the score
of RD1 selected peptides responders at the time of TB
diagnosis. At the end of treatment, 7 subjects (instead of
9) turned negative, and the individual who scored nega-
tive at enrolment was still negative after therapy
Figure 1 Longitudinal analysis of IP-10 levels in NIL and DMSO conditions after 1-day culture in samples from patients with active TB
who were followed until specific therapy completion. IP-10 levels in the NIL (A) and DMSO (B) conditions after 1-day culture in samples
from patients with active TB evaluated before therapy (T0) and at therapy completion (T6). No significant changes were recorded, as indicated
by the p values. Abbreviations: IP: interferon inducible protein. DMSO: Dimethyl Sulfoxide.
Figure 2 Longitudinal analysis of IP-10 secretion in response to the QFT-IT antigens in patients with active TB who were followed
until specific therapy completion: comparison with IFN-g results. IP-10 response to the QFT-IT antigens (A) and IFN-g response (QFT-IT) (B)
in patients with active TB evaluated before therapy (T0) and at therapy completion (T6). No significant changes were recorded, as indicated by
the p values. Abbreviations: IP: interferon inducible protein; IFN: interferon; IU: international units.
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completion. The proportion of positive responders was
still significantly different between baseline and therapy
completion (9/17, 52.9%) (p = 0.02).
The changes in the secretion of IFN-g or IP-10 in
response to QFT-IT antigens or RD1 selected peptides
did not depend on the grade of smear positivity, sputum
culture positivity or severity of TB disease based on the
chest X-ray results at the time of recruitment (data not
shown).
Discussion
In this exploratory study, we demonstrated (for the first
time to our knowledge) that the IP-10 secreted response
to selected RD1 peptides decreases during specific treat-
ment in patients with active TB. A significant quantita-
tive decrease in the level of IP-10 in response to the RD1
selected peptides was found between the baseline and
end of TB treatment accompanied by a significant
decrease in the positive rate of the test. Similar results
were obtained by the detection of IFN-g, confirming our
previous reports [18,30]. Differently, the IP-10 response
to the QFT-IT antigens did not significantly change by
either quantitative or qualitative analysis. Interestingly,
when considering the IFN-g data, the quantitative
responses to QFT-IT decreased, although not signifi-
cantly, from baseline to the end of TB treatment whereas
no change was found in the proportion of responders.
Previous studies have reported a decline in the levels
of IP-10 in plasma after successful anti-TB treatment
[39] and other earlier observations have demonstrated
that patients with active TB have higher IP-10 levels in
the plasma of unstimulated culture when compared to
controls [40,43]. However in this study we were unable
to confirm these data, probably due to the small number
of patients analyzed.
The earlier studies conducted to assess the secretion
of IFN-g in response to QFT-IT ended up with conflict-
ing results among those with active TB. While some of
the studies reported significantly reduced IFN-g secre-
tion at the time of therapy completion compared to the
baseline [9,18-20,22,26,30], other reports showed
unchanged or minimal IFN-g secretion upon effective
therapy [21,23-25]. The probable reasons for this con-
troversy might be due to several factors including re-
infection, persistent infection, persistent exposure to
mycobacteria, and possible maintenance of the circulat-
ing pool of effector memory T cells, rather than techni-
cal factors [7].
IP-10 secretion was elevated in active TB patients after
stimulation with M. tuberculosis antigens [31-36,40,43,44].
However, similar to IFN-g, the IP-10 secretion in response
to the QFT-IT antigens did not change upon effective
therapy. This is not unexpected, as IP-10 secretion is
mainly induced by antigen-specific IFN-g secreting T cells.
Furthermore, previously [33,33], we found a good correla-
tion between the level of IFN-g and IP-10 in subjects with
TB infection. Interestingly, in contrast to QFT-IT antigens,
we found decreased IFN-g and IP-10 levels after overnight
Table 2 IP-10 and IFN-g cut-off points employed for the assays
IP-10 IFN-g
Antigen IP-10 (pg/ml) Cut-off point provided by: IFN-g (IU/ml) Cut-off point provided by:
QFT-IT antigens* 698 ROC analysis [36] 0.35 [company, 44]
RD1 selected peptides 350 ROC analysis [36] 0.57 ROC analysis [33]
Abbreviations: *antigens used in QuantiFERON TB Gold In tube test format; TB: tuberculosis; IP: inducible protein; IFN: interferon; RD: region of difference; ROC:
Receiver Operator Characteristics.
Table 3 Serial response to the IP-10-based and IFN-g-based assays in patients with active TB
QFT-IT antigens RD1 selected peptides IFN-g cut-off 0.57 IU/ml
Time points Time points
T0 T6 p value T0 T6 p value
IP-10
Positive over total (%)
16/17 (94.1) 14/17 (82.3) 0.6 16/17 (94.1) 7/17 (41.1) 0.002
IFN-g
Positive over total (%)
17/17 (100) 14/17 (82.3) 0.2 16/17 (94.1) 7/17 (41.1) 0.002
IP-10
N of reversion over total (%)
- 3/17 (17.6) - 10/17 (58.8)
IP-10 N of conversion over total (%) - 1/17 (5.8) - 0/17 (0)
IFN-g
N of reversion over total (%)
- 3/17 (17.6) - 9/17 (52.9)
IFN- g
N of conversion over total (%)
- 0/17 (0) - 0/17 (0)
Footnotes: TB: tuberculosis; QFT-IT: QuantiFERON TB Gold In tube; IP: inducible protein; IFN: interferon; RD: region of difference; N: number; T0: baseline; T6: end
of treatment.
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stimulation with selected RD1 peptides after successful
therapy.
The difference in the levels of IP-10 and IFN-g secre-
tion between QFT-IT antigens and selected RD1 pep-
tides might be related to the amount and the
composition of epitopes covered by the peptides used in
the two different tests. For example, the peptides
employed in the QTF-IT cover the whole CFP-10 and
ESAT-6 intact proteins (in addition to having a peptide
from TB7.7 from the RD11 region) [41] whereas the
peptides used in our assay are few and selected in order
to be highly immunogenic [27,28]. The response is
mediated by the CD4+ T cells with an effector memory
phenotype, as previously shown [45]. Based on our data,
this oligoclonal response (more than polyclonal against
all RD1 epitopes) appears to be a sensitive tool for mon-
itoring M. tuberculosis replication [17], as well as active
TB disease [18,30].
In the present study we show that both the proportion
of IFN-g and IP-10 positive responders to RD1 selected
peptides was significantly lower after successful therapy
compared to baseline. It is important to note that the
CFP-10 selected peptides induced a stronger and more
frequently observed immune response compared to
ESAT-6 peptides (data not shown) which emphasizes the
need of pooling CFP-10 and ESAT-6 peptides together.
This exploratory study has some limitations. It was
conducted on a small number of subjects (17 out of the
41 initially enrolled). The proportion of responders to
RD1 selected peptides was higher compared (94%) to
previous studies conducted in HIV-uninfected subjects
(around 70%) [29,33], and the BCG status of the
patients was unknown. BCG coverage in India is high
though and we may expect that the majority of the
population studied is BCG-vaccinated [46]. Another lim-
itation is related to the cut-off points used to evaluate
the response to treatment. These were found by ROC
analysis after comparing the results obtained in healthy
subjects with patients with active TB before treatment
[30,33,36,47]. Consequently they may not be correct
when evaluating the response to treatment and greater
efforts to find more accurate cut-off points for treat-
ment efficacy should be made. Indeed based on the cut-
off used, the assay based on RD1 selected peptides is
inferior to the sputum smear as a means to detect fail-
ure. However, despite these limitations, the prospective
design of the study, the evaluation of 4 in vitro assays
for TB diagnosis (3 experimental and 1 commercial) and
the consistency of the data found between the 2 markers
used to evaluate the RD1 responses render the results
solid and interesting.
Conclusions
In conclusion, we are showing (for the first time to our
knowledge) that IP-10 response to the QFT-IT antigens
might be a useful biomarker for monitoring therapy effi-
cacy in patients with active TB. Similar results were
obtained in our previous reports using IFN-g [18,30].
Therefore, there is no real difference between the two
biomarkers (IFN-g and IP-10) other than the magnitude
of the response (greater than 20 fold). Additional studies
performed on a larger number of individuals in both
high and low burden TB settings are needed to evaluate
the consistency of these results.
Figure 3 Longitudinal analysis of IP-10 secretion in response to the RD1 selected peptides in patients with active TB who were
followed until specific therapy completion: comparison with the IFN-g results. IP-10 (A) and IFN-g response (B) to the RD1 selected
peptides in patients with active TB evaluated before therapy (T0) and at therapy completion (T6). Significant changes were recorded, as indicated
by the p values. Abbreviations: IP: interferon inducible protein; IFN: interferon; IU: international units.
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